| Dr Leland G Siwek, MD | |
|
62 W 7th Ave Ste 110, Spokane, WA 99204-2321 | |
| (509) 456-0262 | |
| (509) 462-5059 |
| Full Name | Dr Leland G Siwek |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery (cardiothoracic Vascular Surgery) |
| Location | 62 W 7th Ave Ste 110, Spokane, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801894811 | NPI | - | NPPES |
| 1043025 | Medicaid | WA | |
| G8870921 | Other | WA | MEDICARE PTAN |
| 11106981 | Other | ID | MEDICARE PTAN |
| G8878302 | Other | WA | MEDICARE PTAN |
| 004254400 | Medicaid | ID |
| Entity Name | Providence Health & Services-wa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538311287 PECOS PAC ID: 7911069703 Enrollment ID: O20090105000365 |
News Archive
A Georgetown University Medical Center physician renowned for his research in melanoma will lead a new national clinical trial involving novel treatments for the disease. The study compares the sequencing of two groups of drugs - both effective in treating melanoma.
Supernus Pharmaceuticals, Inc. today announced that its Phase IIa U.S. clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability, and showed statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
CQ HealthBeat reports on reactions to Cindy Mann's appointment as Director of the Center for Medicaid and State Operations, noting that liberals are hailing her appointment and "saying she'll counter steps taken by the Bush administration to tighten eligibility and alter benefits."
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Leland G Siwek, MD 62 W 7th Ave Ste 110, Spokane, WA 99204-2321 Ph: (509) 456-0262 | Dr Leland G Siwek, MD 62 W 7th Ave Ste 110, Spokane, WA 99204-2321 Ph: (509) 456-0262 |
News Archive
A Georgetown University Medical Center physician renowned for his research in melanoma will lead a new national clinical trial involving novel treatments for the disease. The study compares the sequencing of two groups of drugs - both effective in treating melanoma.
Supernus Pharmaceuticals, Inc. today announced that its Phase IIa U.S. clinical trial of SPN-812 in adults for the treatment of attention deficit hyperactivity disorder (ADHD) met the primary endpoints of safety and tolerability, and showed statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
CQ HealthBeat reports on reactions to Cindy Mann's appointment as Director of the Center for Medicaid and State Operations, noting that liberals are hailing her appointment and "saying she'll counter steps taken by the Bush administration to tighten eligibility and alter benefits."
› Verified 2 days ago
Dr. Steven J. Nisco, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 62 W 7th Ave Ste 110, Spokane, WA 99204 Phone: 509-456-0262 Fax: 509-462-5059 | |
Dr. Donald Vernon Holbert, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 122 W 7th Ave, Ste 110, Spokane, WA 99204 Phone: 509-456-0262 Fax: 509-462-5059 | |
Matthew Donavon Forrester, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 62 W 7th Ave Ste 110, Spokane, WA 99204 Phone: 509-456-0262 Fax: 509-462-5059 | |
Dr. Branden R. Reynolds, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 62 W 7th Ave Ste 110, Spokane, WA 99204 Phone: 509-456-0262 Fax: 509-462-5059 | |
Kai A Ihnken, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 122 W 7th Ave Ste 110, Spokane, WA 99204 Phone: 509-462-6485 Fax: 509-462-5059 | |
Dr. Neil K. Worrall, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 62 W 7th Ave Ste 110, Spokane, WA 99204 Phone: 509-456-0262 Fax: 509-462-5059 | |
Justin Reeves, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 62 W 7th Ave Ste 110, Spokane, WA 99204 Phone: 509-456-0262 |